) and partner Bristol-Myers Squibb presented data on their
anti-clotting drug Eliquis (apixaban) at the 2013 ESC Congress in
the Netherlands. The companies presented the results on Eliquis
from a subanalysis of the phase III ARISTOTLE study.
The study evaluated the efficacy and safety of Eliquis versus
warfarin for the preventing stroke or systemic embolism in
patients suffering from nonvalvular atrial fibrillation (NVAF).
Atrial fibrillation refers to a cardiac rhythm disorder
characterized by an erratic heartbeat.
The subanalysis evaluated Eliquis versus warfarin in 4,808 NVAF
patients (26.4% of the patients evaluated in the ARISTOTLE study)
with or without other types of valvular heart disease. Data from
the subanalysis was found to be consistent with the results of
the overall ARISTOTLE study.
In particular, data revealed that treatment with Eliquis
reduced stroke or systemic embolism, caused fewer major bleeding
events and reduced all-cause mortality compared to those treated
Late last month, Pfizer and Bristol-Myers presented results from
a post-hoc sub-analysis of the ARISTOTLE trial at the ESC
Congress 2013. The sub-analysis was carried out to determine the
overall rates of key post-procedural outcomes, such as stroke or
systemic embolism and major bleeding, among Eliquis and warfarin
patients who underwent a procedure during the ARISTOTLE trial.
The sub-analysis also examined differences in post-procedural
events according to whether or not the study drug was
The companies said that in the 30-day period following a
procedure, rates of clinical events (stroke or systemic embolism,
major bleeding, and all-cause death) were comparable in the
Eliquis and warfarin arms.
BAYER A G -ADR (BAYRY): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Event rates in the 30-day period following a procedure in
patients in the Eliquis arm were similar irrespective of Eliquis
being stopped prior to the procedure or continued during the
procedure. However, in the warfarin arm, a minimum twofold higher
rate of major bleeding and death was observed during the 30-day
period following a procedure when warfarin was continued during
the procedure compared to when warfarin was stopped before the
We note that the anti-coagulant market currently includes
ohnson & Johnson
) blood-thinner Xarelto. Moreover, the arrival of Boehringer
Ingelheim's Pradaxa has intensified competition in the market.
Pfizer carries a Zacks Rank #3 (Hold). Pfizer's second quarter
2013 results were mixed with earnings slightly above expectations
and revenues continuing to lag expectations. We believe revenues
will remain under pressure due to genericization and the
expiration of a few co-promotion agreements. However,
cost-cutting efforts and share buybacks should help the company
achieve its 2013 earnings guidance. Pfizer expects earnings of
$2.10 - $2.20 per share in 2013.
Gilead Sciences Inc.
) appears to be very attractive with a Zacks Rank #1 (Strong